Crohn's Disease Supplements: Evidence-Graded Guide

The supplements with the strongest evidence for Crohn's disease are vitamin D3 (50 to 70% of Crohn's patients are deficient; serum levels correlate inversely with disease activity), curcumin (Grade B: Hanai 2006 RCT showed relapse dropped from 20.5% to 4.7%), and zinc carnosine (Grade B: mucosal repair via tight junction protein expression). Some supplements actively worsen Crohn's. Oral iron during active flares increases intestinal inflammation through reactive oxygen species and bacterial iron utilization. Uncoordinated folic acid taken on the same day as methotrexate reduces the drug's efficacy. Every dosage recommendation below should be discussed with your gastroenterologist before starting.

Why Crohn's Patients Need Supplements

Crohn's disease inflames the small bowel, the primary site of nutrient absorption. Ileal disease (the most common location) impairs absorption of vitamin B12, bile salts, and fat-soluble vitamins. Surgical resection removes absorptive surface permanently. Even patients in clinical remission may carry subclinical deficiencies from years of impaired absorption.

The numbers are stark. Vitamin D deficiency affects 50 to 70% of Crohn's patients. Iron deficiency affects 30 to 60%. B12 malabsorption is nearly universal in ileal disease. Folate depletion compounds when patients take methotrexate or sulfasalazine, both of which interfere with folate metabolism.

Two categories of supplementation matter here, and the distinction is important. Deficiency correction (replacing what the inflamed gut fails to absorb) is medically necessary regardless of the evidence for therapeutic benefit. Therapeutic supplementation (using higher doses to actively modulate inflammation or promote mucosal healing) requires stronger evidence to justify. The grades below reflect this distinction.

How We Grade Evidence

Three tiers, based on the quality of human data available for each intervention.

Grade A: Multiple randomized controlled trials (RCTs) or meta-analyses in autoimmune populations. Consistent, reproducible results.

Grade B: At least one RCT, strong case series, or robust mechanistic evidence paired with clinical observations. Promising but not definitive.

Grade C: Preliminary evidence only. Animal studies, in vitro data, or small pilot trials.

Grades are condition-specific. A supplement earning Grade A for Hashimoto's may earn Grade C for Crohn's if the Crohn's-specific trial data is thin. For a cross-condition overview, see our best supplements for autoimmune disease guide.

Grade A Interventions (Deficiency Correction)

Vitamin D3 + K2

The VITAL trial (Hahn et al., 2022, BMJ) randomized 25,871 adults to 2,000 IU/day vitamin D3 or placebo over 5.3 years. The vitamin D group developed 22% fewer confirmed autoimmune diseases. In years 4 and 5, the reduction reached 39%.

The Crohn's-specific data aligns. A study comparing Crohn's patients in remission versus those with active disease found mean serum 25(OH)D levels of 27 ng/mL in the active group versus 38 ng/mL in remission (PMC 4077052). The relationship runs in both directions: low vitamin D predicts flares, and active flares deplete vitamin D through inflammation-driven catabolism.

Vitamin D is not merely a bone nutrient. The vitamin D receptor (VDR) sits on nearly every immune cell. Activation promotes regulatory T cell expansion, suppresses Th17 differentiation (the T cell subset driving intestinal inflammation in Crohn's), and strengthens tight junction protein expression in the intestinal epithelium. For a disease defined by barrier failure and Th17 overactivity, this mechanism is directly relevant.

Corticosteroids, used frequently in Crohn's flare management, accelerate vitamin D depletion and bone density loss. Patients cycling through prednisone courses face compounding deficiency with each round.

Dosing: 2,000 to 5,000 IU/day vitamin D3 paired with 100 to 200 mcg vitamin K2 (MK-7 form). K2 directs calcium into bone rather than arteries. Test serum 25(OH)D every 3 months until stable. Target: 40 to 60 ng/mL. Discuss your dose with your gastroenterologist, particularly if you have stricturing disease or short bowel syndrome, as fat-soluble vitamin absorption may be further impaired.

Vitamin B12

Ileal Crohn's disease or ileal resection creates a straightforward absorption problem. The terminal ileum is the exclusive site of intrinsic factor-mediated B12 absorption. When that tissue is inflamed or surgically absent, oral B12 tablets pass through the GI tract unabsorbed.

B12 deficiency produces fatigue, cognitive impairment, peripheral neuropathy, and macrocytic anemia. These symptoms overlap with active Crohn's disease, making deficiency easy to misattribute to the underlying condition. Serum B12 alone can miss early deficiency. Methylmalonic acid (MMA) is a more sensitive functional marker; an elevated MMA with low-normal B12 confirms tissue-level depletion.

Dosing: For patients with ileal disease or resection, sublingual methylcobalamin (1,000 mcg/day) or intramuscular B12 injection (1,000 mcg monthly or as directed) bypasses the impaired absorption pathway. Standard oral cyanocobalamin tablets are insufficient when the terminal ileum is compromised. Discuss testing and route of administration with your doctor.

Folate / Methylfolate

Methotrexate depletes folate by design. The drug works by inhibiting dihydrofolate reductase, and folate supplementation (1 mg daily or 5 mg weekly) is medically required to reduce methotrexate side effects: nausea, mouth sores, bone marrow suppression, and liver enzyme elevation. Sulfasalazine also impairs folate absorption through a different mechanism.

One timing rule is critical and frequently violated. Folate must be taken on a different day than methotrexate. Same-day administration reduces methotrexate's therapeutic efficacy by competing for the same enzymatic pathway. Many patients receive this instruction from their pharmacist. Many do not. The result is either inadequate disease control (folate taken same day, blunting methotrexate) or avoidable side effects (folate not taken at all).

Dosing: 1 mg folic acid daily or 5 mg once weekly. Take 24 to 48 hours after methotrexate dosing. Methylfolate (5-MTHF) is an alternative for patients with MTHFR polymorphisms, though the clinical significance of routine MTHFR testing remains debated. Discuss timing with your prescribing physician.

Grade B Interventions (Therapeutic Evidence)

Curcumin

Hanai et al. (2006, PubMed 17101300) conducted a randomized, double-blind, placebo-controlled trial in 89 patients with quiescent ulcerative colitis. Patients received either 2 g/day curcumin or placebo alongside standard mesalamine therapy. Over 6 months, relapse occurred in 4.65% of the curcumin group versus 20.51% of placebo. The difference was statistically significant (p = .040). Lang et al. (2015) found that curcumin added to mesalamine nearly doubled clinical remission rates in active UC induction.

A caveat: both landmark trials studied ulcerative colitis, not Crohn's disease. The conditions share inflammatory pathways (NF-kB activation, TNF-alpha overproduction, tight junction degradation) but differ in location, depth of inflammation, and immunological profile. Extrapolation from UC to CD is reasonable on mechanistic grounds but imperfect. No large Crohn's-specific curcumin RCT has been published.

Curcumin inhibits NF-kB, the master inflammatory transcription factor that drives TNF-alpha, IL-1beta, and IL-6 production. It also upregulates tight junction proteins (claudins and occludin) in intestinal epithelial cells, directly addressing the barrier dysfunction central to IBD pathology.

Bioavailability is the practical barrier. Standard turmeric powder delivers roughly 3% curcumin by weight, and curcumin itself is poorly absorbed, rapidly metabolized, and quickly eliminated. Clinical trials use bioavailability-enhanced formulations: curcumin with piperine (black pepper extract, which increases absorption approximately 2,000%), phytosomal forms, or liposomal delivery. Cooking with turmeric is not therapeutic supplementation.

Dosing: 2 g/day of bioavailable curcumin with piperine, split into two doses with meals. Curcumin has mild anticoagulant properties. Discuss with your doctor if you take blood thinners. Patients on biologics (anti-TNF agents like infliximab) should note that curcumin modulates the same NF-kB pathway; no adverse interaction has been documented, but inform your gastroenterologist.

Zinc Carnosine

Zinc carnosine (brand name Polaprezinc in Japan, where it has been used clinically since 1994) promotes mucosal repair through several documented mechanisms. It stabilizes tight junction protein expression, stimulates mucosal blood flow, and protects against oxidative damage to the intestinal lining. Matsukura and Tanaka (2000) demonstrated improved mucosal integrity in patients with gastric ulceration.

For Crohn's disease specifically, tight junction dysfunction is a defining feature. Fasano's research on intestinal permeability established that increased zonulin signaling opens tight junctions, allowing luminal antigens to cross the epithelial barrier and trigger immune activation. Zinc carnosine works at this precise failure point by strengthening the junctions that Crohn's disease degrades.

Zinc deficiency is common in Crohn's patients due to malabsorption, diarrhea-related losses, and reduced dietary intake during flares. The carnosine chelation form offers two advantages over other zinc formulations: it adheres to the gastric and intestinal mucosa for prolonged local contact, and it causes less nausea than zinc sulfate or zinc gluconate.

Dosing: 75 to 150 mg twice daily on an empty stomach. The empty-stomach timing allows zinc carnosine to contact the mucosal surface directly before food dilutes it. Discuss with your doctor. High-dose zinc (above 40 mg elemental zinc daily for extended periods) can deplete copper; monitor copper levels if supplementing long term.

Iron (Route Matters Critically)

Iron deficiency anemia affects 30 to 60% of Crohn's patients. Blood loss from inflamed mucosa, impaired duodenal absorption, and chronic inflammation (which upregulates hepcidin, blocking iron release from storage) all contribute.

The supplementation route is a clinical decision with real consequences. Oral iron during active Crohn's flares worsens intestinal inflammation. The mechanism is well characterized (PMC 7697745): unabsorbed iron in the intestinal lumen generates reactive oxygen species through Fenton chemistry, damages the already-compromised mucosa, and feeds pathogenic gut bacteria (many of which are iron-dependent for virulence factor expression). A study comparing oral versus intravenous iron in active IBD found that oral iron increased fecal calprotectin (an inflammation marker) while IV iron did not.

IV iron (ferric carboxymaltose or iron sucrose) bypasses the gut entirely. For patients with active disease or moderate-to-severe anemia (hemoglobin below 10 g/dL), IV iron is the standard of care in IBD guidelines from the European Crohn's and Colitis Organisation (ECCO).

Dosing: Oral iron is appropriate only for quiescent Crohn's disease with mild anemia (hemoglobin above 10 g/dL). Ferrous bisglycinate causes less GI irritation than ferrous sulfate. For active disease, IV iron administered by your gastroenterologist is safer and more effective. Discuss your hemoglobin, ferritin, and disease activity with your doctor before choosing a route.

Omega-3 EPA + DHA (Honest Assessment)

The EPIC trial (Feagan et al., 2008) was the definitive test. This large, well-designed RCT randomized 363 Crohn's patients in remission to 4 g/day enteric-coated fish oil or placebo. The primary outcome: no significant difference in relapse rates at one year. A Cochrane review subsequently concluded that omega-3 fatty acids are "probably ineffective" for maintaining remission in Crohn's disease.

That does not mean omega-3 is worthless for Crohn's patients. EPA and DHA serve as precursors to specialized pro-resolving mediators (resolvins, protectins, maresins) that actively terminate inflammatory cascades. They reduce TNF-alpha and IL-6 production. They improve the omega-6 to omega-3 ratio, which is consistently skewed toward pro-inflammatory arachidonic acid metabolites in IBD patients.

The disconnect between mechanism and clinical outcome likely reflects the complexity of Crohn's inflammation. Omega-3 modulates one arm of the inflammatory response. Crohn's disease involves T cell driven, granulomatous inflammation with multiple redundant pathways. Modulating one pathway is insufficient to prevent relapse, even if it reduces certain biomarkers.

Dosing: 2 to 4 g combined EPA + DHA per day with meals. Realistic expectations: anti-inflammatory support and cardiovascular protection, not flare prevention. Doses above 3 g/day have anticoagulant properties; discuss with your doctor if you take blood thinners. Triglyceride-form fish oil absorbs better than ethyl ester forms.

Probiotics: The Honest Assessment

The evidence for probiotics in IBD splits sharply by disease. VSL#3 (a high-dose, multi-strain formulation containing 450 to 900 billion CFU per sachet) has Grade B evidence for UC pouchitis prevention and maintenance. For Crohn's disease, the evidence does not support routine use.

Saccharomyces boulardii is frequently recommended in integrative gastroenterology circles for Crohn's. Bourreille et al. (2013, PubMed 23466709) tested this directly in a randomized, double-blind trial of 165 Crohn's patients in remission. The result: no significant difference in relapse rates between S. boulardii and placebo at 52 weeks. The study was adequately powered and well designed. The yeast probiotic did not work for Crohn's maintenance.

General-purpose probiotic supplements (Lactobacillus, Bifidobacterium blends at 10 to 50 billion CFU) lack Crohn's-specific RCT support. They may improve subjective symptoms in some patients. They have not been shown to alter disease course, reduce fecal calprotectin, or prevent relapse in controlled trials.

The microbiome in Crohn's disease is profoundly dysbiotic: reduced Faecalibacterium prausnitzii (a key butyrate producer), increased adherent-invasive E. coli, and diminished overall diversity. Whether adding exogenous probiotic strains can meaningfully shift this ecology is an open question. The current evidence says they cannot, at least not with the strains and doses tested so far.

Practical takeaway: If you currently take probiotics and feel they help your symptoms, continuing is unlikely to cause harm. Starting probiotics specifically to prevent Crohn's relapse is not supported by the trial data. Discuss with your gastroenterologist.

Supplements to Avoid with Crohn's Disease

Oral iron during active flares. Covered in detail above. Unabsorbed iron in the inflamed intestinal lumen generates reactive oxygen species, damages mucosa, and promotes pathogenic bacterial growth. Request IV iron from your gastroenterologist instead.

Insoluble fiber supplements. Patients with stricturing Crohn's disease face a mechanical risk. Insoluble fiber (psyllium husk in large doses, wheat bran, flax meal) can accumulate proximal to a narrowed intestinal segment, causing obstruction. Soluble fiber (partially hydrolyzed guar gum, acacia fiber) is generally tolerated and may support short-chain fatty acid production. Know your disease phenotype before adding fiber.

Immune-stimulating supplements. Echinacea, elderberry, spirulina, chlorella, ashwagandha, and astragalus all stimulate immune cell activation. Crohn's disease is driven by overactive Th1 and Th17 immune responses. Stimulating the immune system further is contraindicated. For a detailed list of immune-stimulating supplements to avoid across autoimmune conditions, see our best supplements for autoimmune disease guide.

High-dose vitamin C (above 1,000 mg/day). Vitamin C in large doses causes osmotic diarrhea, compounding an already significant problem for Crohn's patients. High-dose vitamin C also increases methotrexate toxicity by altering renal clearance. Moderate dietary vitamin C from food is sufficient.

Uncoordinated folic acid. Folate taken on the same day as methotrexate reduces the drug's efficacy. This is a timing problem, not a supplement problem. Take folate 24 to 48 hours after methotrexate.

Drug-Supplement Interactions

Five medication classes cover the majority of Crohn's pharmacotherapy. Each carries supplement interactions that determine safe combinations.

Methotrexate. Folate supplementation required but on a different day (see above). High-dose vitamin C (above 1,000 mg) may increase toxicity. NAC theoretically interacts with methotrexate's mechanism; avoid without gastroenterology consultation.

Sulfasalazine. Depletes folate through impaired absorption. Supplement 1 mg folate daily. Separate the two by at least 2 hours to minimize absorption interference.

Corticosteroids (prednisone, budesonide). Accelerate bone loss: add calcium (1,000 mg/day) and vitamin D3. Deplete magnesium via increased renal excretion. Raise blood glucose; patients on prednisone should avoid supplements with added sugars. Budesonide has lower systemic absorption and fewer of these effects, but long-term use still warrants monitoring.

Biologics (infliximab, adalimumab, vedolizumab). Vitamin D supplementation is compatible and may improve biologic response through shared immune modulation pathways. Curcumin targets NF-kB, the same pathway biologics modulate; no adverse interaction documented. Inform your gastroenterologist about all supplements when starting biologic therapy.

Azathioprine / 6-mercaptopurine. NAC may interact with thiopurine metabolism through effects on glutathione conjugation. Avoid high-dose antioxidant supplements without gastroenterology consultation. Standard doses of vitamin D, omega-3, and zinc carnosine are considered safe.

Advanced Options

Low Dose Naltrexone (LDN)

Smith et al. conducted a Phase 2 trial of LDN (4.5 mg nightly) in active Crohn's disease. The results: 88% response rate and 33% complete remission, measured by a CDAI decrease of at least 70 points. Endoscopic improvement was documented in a subset of responders. The mechanism involves transient opioid receptor blockade, which triggers upregulation of endogenous opioid production (endorphins, enkephalins) and modulation of immune cell function through opioid growth factor receptor (OGFr) signaling.

LDN is a prescription medication used off-label. It requires a compounding pharmacy (standard naltrexone tablets are 50 mg; LDN doses are 1.5 to 4.5 mg). The Phase 2 data is compelling but has not been replicated in a large Phase 3 trial. For a comprehensive review of the evidence, see our low dose naltrexone for autoimmune disease guide. Discuss with your gastroenterologist.

BPC-157

BPC-157 (Body Protection Compound-157) is a synthetic peptide derived from human gastric juice that has shown remarkable effects on mucosal healing in animal models. Sikiric et al. documented accelerated healing of gastric ulcers, colitis lesions, NSAID-induced intestinal injury, and even intestinal fistulas in rat models. The mechanism involves upregulation of VEGF (vascular endothelial growth factor), nitric oxide system modulation, and angiogenesis at injury sites.

No human randomized controlled trial exists. BPC-157 is not FDA-approved. It was added to the WADA banned substance list in 2022. The animal data is extensive and consistent, but the translation gap to human IBD remains uncharted. For a full analysis of the evidence and comparison with established gut-healing compounds, see our BPC-157 for gut healing guide.

Diet: SCD and Mediterranean (DINE-CD Trial)

Lewis et al. (2021, Gastroenterology) published the DINE-CD trial, a multicenter RCT comparing the Specific Carbohydrate Diet (SCD) to a Mediterranean diet in 194 adults with mild-to-moderate Crohn's disease. Both diets produced clinical improvement, but neither was superior to the other. Symptomatic remission rates at 6 weeks were comparable between arms.

The finding reframes the dietary conversation for Crohn's patients. A strict SCD (which eliminates all grains, most sugars, and many starches) is difficult to maintain long-term. The Mediterranean diet achieves similar outcomes with substantially greater dietary flexibility and better long-term adherence. For patients struggling with the restrictiveness of elimination diets, the DINE-CD data offers a practical alternative. The autoimmune protocol (AIP) diet shares significant overlap with Mediterranean principles while adding targeted eliminations; see our AIP diet guide for details.

Supplement Timing Schedule

Splitting supplements across the day optimizes absorption and reduces GI burden, a meaningful consideration for a disease that already causes GI distress. This schedule assumes you are taking the recommended interventions; adjust based on which supplements your gastroenterologist has approved.

Morning (empty stomach, 30 minutes before food): Zinc carnosine 75 to 150 mg (direct mucosal contact before food dilutes it). Probiotics if used.

With breakfast: Vitamin D3 (2,000 to 5,000 IU) + K2 (100 to 200 mcg). Omega-3 half dose (1 to 2 g EPA + DHA). Folate 1 mg (not on methotrexate day). Fat-soluble supplements require dietary fat for absorption.

With lunch: Curcumin 1 g with piperine. Omega-3 remaining dose (1 to 2 g).

Evening (with dinner or before bed): Zinc carnosine second dose (75 to 150 mg). Magnesium glycinate 200 to 400 mg. B12 1,000 mcg sublingual if deficient. Curcumin second dose if using 2 g/day split dosing.

If you take azathioprine or methotrexate, separate mineral supplements from your medication dose by at least 2 hours.

Frequently Asked Questions

What are the best supplements for Crohn's disease?

Vitamin D3 has the strongest combined evidence (deficiency correction plus therapeutic benefit). The VITAL trial showed 22% autoimmune risk reduction, and Crohn's-specific data links higher serum levels to remission. Curcumin (Grade B) reduced UC relapse from 20.5% to 4.7% in the Hanai 2006 RCT, with reasonable mechanistic extrapolation to Crohn's. Zinc carnosine (Grade B) supports mucosal repair through tight junction protein expression. B12 and folate correction are medically necessary for patients with ileal disease or on methotrexate/sulfasalazine.

Do probiotics help Crohn's disease?

The honest answer: the current evidence does not support routine probiotic use for Crohn's maintenance. S. boulardii failed in a well-designed RCT of 165 patients (Bourreille 2013). VSL#3 has evidence for UC pouchitis but not for Crohn's specifically. Individual patients may experience subjective improvement in symptoms, and continuing probiotics that seem helpful is unlikely to cause harm. Starting probiotics specifically to prevent Crohn's relapse is not supported by trial data.

Should Crohn's patients take iron supplements?

Iron deficiency affects 30 to 60% of Crohn's patients and should be treated. The critical distinction is route. Oral iron during active flares worsens intestinal inflammation through reactive oxygen species generation and promotion of pathogenic bacteria. IV iron (ferric carboxymaltose or iron sucrose) is the preferred route for active disease per ECCO guidelines. Oral iron is appropriate only during quiescent disease with mild anemia. Always discuss iron status and administration route with your gastroenterologist.

Can I take curcumin with my Crohn's medication?

Curcumin is generally compatible with standard Crohn's medications including mesalamine, biologics (infliximab, adalimumab), and corticosteroids. Curcumin targets NF-kB signaling, the same inflammatory pathway modulated by biologics, with no documented adverse interaction. Two cautions: curcumin has mild anticoagulant properties (discuss if you take blood thinners), and the landmark RCTs were conducted in UC rather than Crohn's disease. Inform your gastroenterologist about curcumin supplementation when starting or adjusting Crohn's medications.

What supplements should I avoid during a Crohn's flare?

Oral iron (generates reactive oxygen species in inflamed gut), insoluble fiber supplements (obstruction risk with strictures), high-dose vitamin C above 1,000 mg (osmotic diarrhea, methotrexate toxicity), and all immune-stimulating supplements (echinacea, elderberry, spirulina, ashwagandha). Folic acid should still be taken during flares if you are on methotrexate, but on a different day than the drug dose. Vitamin D, omega-3, and zinc carnosine can generally be continued through flares. If you experience autoimmune disease symptoms beyond your usual pattern, contact your gastroenterologist before adjusting any supplements.

Building Your Crohn's Protocol

Start with deficiency correction. Test vitamin D, B12, folate, iron, and zinc levels. Correct what is low. This step requires no debate about therapeutic evidence; these are documented deficiencies caused by the disease itself.

Add curcumin (2 g/day with piperine) and zinc carnosine (75 to 150 mg twice daily) as the first therapeutic additions. Both target mucosal healing and barrier function, the core structural problems in Crohn's disease.

Approach omega-3 with realistic expectations. Anti-inflammatory support, yes. Flare prevention, no.

Avoid everything on the "supplements to avoid" list. Check ingredient labels on multivitamins, greens powders, and immune-support blends for hidden echinacea, spirulina, or ashwagandha.

Consider LDN as a discussion point with your gastroenterologist if standard therapy provides incomplete relief. The Smith Phase 2 data (88% response rate) warrants the conversation.

Your optimal protocol depends on disease location (ileal versus colonic versus ileocolonic), behavior (inflammatory versus stricturing versus penetrating), current medications, and severity. A supplement strategy for quiescent ileal Crohn's on azathioprine differs substantially from one for active colonic Crohn's on infliximab.

Take the free 3-minute AutoimmuneFinder quiz to build a personalized, evidence-graded protocol matched to your specific condition, severity, and current medications.

This article is for educational purposes only and does not constitute medical advice. Crohn's disease is a serious chronic condition requiring ongoing gastroenterological supervision. Do not start, stop, or change any supplement or medication without consulting your gastroenterologist or primary care physician. All dosage recommendations should be discussed with your healthcare provider before implementation.